Tests inotuzumab, blinatumomab and ponatinib in Philadelphia-negative B-cell leukemia
Tests two antibody drugs, with or without ponatinib, in adults with CD22-positive leukemia.
Plain-language title generated from the registry record
Registry title: Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Key facts
- Where
- Aberdeen, Allentown, Alton, Anchorage, Ankeny, Ann Arbor, Arroyo Grande, Atlanta, Ballwin, Baltimore, Bellevue, Bellingham, Bend, Bethlehem, Birmingham, Bloomington, Boise, Bolivar, Branson, Brighton, Buffalo, Burbank, Burr Ridge, Canton, Cape Girardeau, Carbondale, Caro, Carson City, Carterville, Carthage, Centralia, Chadds Ford, Chapel Hill, Chelsea, Chicago, Cincinnati, City of Saint Peters, Clackamas, Clarkston, Clive, Clovis, Columbus, Coos Bay, Creve Coeur, Decatur, Des Moines, Detroit, Dixon, Duarte, Durham, East China Township, East Stroudsburg, Eau Claire, Edmonds, Effingham, Eureka, Evanston, Everett, Farmington, Flint, Fort Lauderdale, Fort Smith, Fruitland, Galesburg, Garden City, Glenview, Great Bend, Greenville, Grosse Pointe Woods, Hazleton, Henderson, Highland Park, Homer Glen, Irvine, Issaquah, Jefferson City, Joplin, Jupiter, Kansas City, Kennewick, Kewanee, Kingman, La Jolla, Lacey, Lake Forest, Lake Success, Lansing, Las Vegas, Lewes, Livonia, Longview, Macomb, Madison, Manhasset, Marlette, Marshfield, Maywood, Melrose Park, Menomonee Falls, Meridian, Millville, Milwaukee, Minocqua, Missoula, Morgantown, Mount Vernon, Nampa, New Berlin, New Hyde Park, New Lenox, New Orleans, New York, Newark, Newberg, O'Fallon, Oak Creek, Oklahoma City, Omaha, Orange, Oregon City, Orland Park, Ottawa, Pahrump, Palo Alto, Pekin, Peoria, Peru, Philadelphia, Pontiac, Portland, Princeton, Redmond, Rehoboth Beach, Reno, Renton, Rice Lake, Richmond, Rochester, Rochester Hills, Rolla, Saginaw, Saint Joseph, Sainte Genevieve, Seaford, Seattle, Sedro-Woolley, Shelton, Springfield, St Louis, Sterling Heights, Stevens Point, Stony Brook, Sullivan, Tawas City, Twin Falls, Vancouver, Walla Walla, Warren, Washington, Washington D.C., Waukee, West Bend, West Branch, West Chester, Weston, Westwood, Wilmington, Winston-Salem, Yakima, Yelm, and Ypsilanti, United StatesSee the 283 sites
- Phase
- Phase 2
Where in United States
- Providence Regional Cancer System-AberdeenAberdeen, United StatesNo longer taking part
- Lehigh Valley Hospital-Cedar CrestAllentown, United StatesNo longer taking part
- OSF Saint Anthony's Health CenterAlton, United StatesNo longer taking part
- Alaska Breast Care and Surgery LLCAnchorage, United StatesNo longer taking part
- Alaska Oncology and Hematology LLCAnchorage, United StatesNo longer taking part
- Alaska Women's Cancer CareAnchorage, United StatesNo longer taking part
- Anchorage Associates in Radiation MedicineAnchorage, United StatesNo longer taking part
- Anchorage Oncology CentreAnchorage, United StatesNo longer taking part
- Anchorage Radiation Therapy CenterAnchorage, United StatesNo longer taking part
- Katmai Oncology GroupAnchorage, United StatesNo longer taking part
- Providence Alaska Medical CenterAnchorage, United StatesNo longer taking part
- UI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny, United StatesTaking people
- Trinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor, United StatesTaking people
- PCR OncologyArroyo Grande, United StatesNo longer taking part
- Emory Saint Joseph's HospitalAtlanta, United StatesTaking people
- Emory University Hospital/Winship Cancer InstituteAtlanta, United StatesTaking people
- Mercy Oncology and Hematology - Clayton-ClarksonBallwin, United StatesNo longer taking part
- University of Maryland/Greenebaum Cancer CenterBaltimore, United StatesNo longer taking part
- Overlake Medical CenterBellevue, United StatesNo longer taking part
- PeaceHealth Saint Joseph Medical CenterBellingham, United StatesNo longer taking part
- Saint Charles Health SystemBend, United StatesNo longer taking part
- Lehigh Valley Hospital - MuhlenbergBethlehem, United StatesNo longer taking part
- University of Alabama at Birmingham Cancer CenterBirmingham, United StatesNo longer taking part
- Illinois CancerCare-BloomingtonBloomington, United StatesNo longer taking part
- Saint Luke's Cancer Institute - BoiseBoise, United StatesNo longer taking part
- Central Care Cancer Center - BolivarBolivar, United StatesNo longer taking part
- Cox Cancer Center BransonBranson, United StatesNo longer taking part
- Trinity Health IHA Medical Group Hematology Oncology - BrightonBrighton, United StatesTaking people
- Trinity Health Medical Center - BrightonBrighton, United StatesTaking people
- Roswell Park Cancer InstituteBuffalo, United StatesNo longer taking part
- Providence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank, United StatesNo longer taking part
- Loyola Center for Health at Burr RidgeBurr Ridge, United StatesNo longer taking part
- Trinity Health IHA Medical Group Hematology Oncology - CantonCanton, United StatesTaking people
- Trinity Health Medical Center - CantonCanton, United StatesTaking people
- Illinois CancerCare-CantonCanton, United StatesNo longer taking part
- Mercy Cancer Center - Cape GirardeauCape Girardeau, United StatesNo longer taking part
- Saint Francis Medical CenterCape Girardeau, United StatesNo longer taking part
- Memorial Hospital of CarbondaleCarbondale, United StatesNo longer taking part
- Caro Cancer CenterCaro, United StatesNo longer taking part
- Carson Tahoe Regional Medical CenterCarson City, United StatesNo longer taking part
- SIH Cancer InstituteCarterville, United StatesNo longer taking part
- Illinois CancerCare-CarthageCarthage, United StatesNo longer taking part
- Centralia Oncology ClinicCentralia, United StatesNo longer taking part
- Providence Regional Cancer System-CentraliaCentralia, United StatesNo longer taking part
- Christiana Care Health System-Concord Health CenterChadds Ford, United StatesNo longer taking part
- UNC Lineberger Comprehensive Cancer CenterChapel Hill, United StatesNo longer taking part
- Chelsea HospitalChelsea, United StatesTaking people
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea, United StatesTaking people
- Northwestern UniversityChicago, United StatesTaking people
- University of Chicago Comprehensive Cancer CenterChicago, United StatesTaking people
- University of IllinoisChicago, United StatesTaking people
- University of Cincinnati Cancer Center-UC Medical CenterCincinnati, United StatesTaking people
- Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, United StatesTaking people
- Clackamas Radiation Oncology CenterClackamas, United StatesTaking people
- Providence Cancer Institute Clackamas ClinicClackamas, United StatesNo longer taking part
- Hematology Oncology Consultants-ClarkstonClarkston, United StatesNo longer taking part
- Newland Medical Associates-ClarkstonClarkston, United StatesNo longer taking part
- UI Health Care Mission Cancer and Blood - West Des Moines ClinicClive, United StatesTaking people
- Community Cancer InstituteClovis, United StatesNo longer taking part
- University Oncology AssociatesClovis, United StatesNo longer taking part
- Ohio State University Comprehensive Cancer CenterColumbus, United StatesTaking people
- Bay Area HospitalCoos Bay, United StatesNo longer taking part
- Siteman Cancer Center at West County HospitalCreve Coeur, United StatesTaking people
- Cancer Care Specialists of Illinois - DecaturDecatur, United StatesTaking people
- Decatur Memorial HospitalDecatur, United StatesNo longer taking part
- UI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines, United StatesTaking people
- UI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines, United StatesTaking people
- Henry Ford Health Saint John HospitalDetroit, United StatesTaking people
- Illinois CancerCare-DixonDixon, United StatesNo longer taking part
- City of Hope Comprehensive Cancer CenterDuarte, United StatesTaking people
- Duke University Medical CenterDurham, United StatesNo longer taking part
- Henry Ford River District HospitalEast China Township, United StatesTaking people
- Pocono Medical CenterEast Stroudsburg, United StatesNo longer taking part
- Marshfield Medical Center-EC Cancer CenterEau Claire, United StatesTaking people
- Swedish Cancer Institute-EdmondsEdmonds, United StatesNo longer taking part
- Crossroads Cancer CenterEffingham, United StatesTaking people
- Illinois CancerCare-EurekaEureka, United StatesNo longer taking part
- NorthShore University HealthSystem-Evanston HospitalEvanston, United StatesTaking people
- Providence Regional Cancer PartnershipEverett, United StatesNo longer taking part
- Parkland Health Center - FarmingtonFarmington, United StatesNo longer taking part
- Cancer Hematology Centers - FlintFlint, United StatesTaking people
- Genesys Hurley Cancer InstituteFlint, United StatesTaking people
- Hurley Medical CenterFlint, United StatesTaking people
- Genesee Hematology Oncology PCFlint, United StatesNo longer taking part
- Holy Cross HospitalFort Lauderdale, United StatesNo longer taking part
- Mercy Hospital Fort SmithFort Smith, United StatesNo longer taking part
- Saint Luke's Cancer Institute - FruitlandFruitland, United StatesNo longer taking part
- Illinois CancerCare-GalesburgGalesburg, United StatesNo longer taking part
- Western Illinois Cancer Treatment CenterGalesburg, United StatesNo longer taking part
- Central Care Cancer Center - Garden CityGarden City, United StatesNo longer taking part
- NorthShore University HealthSystem-Glenbrook HospitalGlenview, United StatesTaking people
- Central Care Cancer Center - Great BendGreat Bend, United StatesNo longer taking part
- East Carolina UniversityGreenville, United StatesNo longer taking part
- Henry Ford Saint John Hospital - AcademicGrosse Pointe Woods, United StatesTaking people
- Henry Ford Saint John Hospital - Van ElslanderGrosse Pointe Woods, United StatesTaking people
- Henry Ford Saint John Hospital - BreastGrosse Pointe Woods, United StatesNo longer taking part
- Lehigh Valley Hospital-HazletonHazleton, United StatesNo longer taking part
- Cancer and Blood Specialists-HendersonHenderson, United StatesNo longer taking part
- Comprehensive Cancer Centers of Nevada - HendersonHenderson, United StatesNo longer taking part
- Comprehensive Cancer Centers of Nevada-Horizon RidgeHenderson, United StatesNo longer taking part
- Comprehensive Cancer Centers of Nevada-Southeast HendersonHenderson, United StatesNo longer taking part
- Las Vegas Cancer Center-HendersonHenderson, United StatesNo longer taking part
- Las Vegas Urology - Green ValleyHenderson, United StatesNo longer taking part
- Las Vegas Urology - PebbleHenderson, United StatesNo longer taking part
- Oncology Las Vegas - HendersonHenderson, United StatesNo longer taking part
- Urology Specialists of Nevada - Green ValleyHenderson, United StatesNo longer taking part
- NorthShore University HealthSystem-Highland Park HospitalHighland Park, United StatesTaking people
- Loyola Medicine Homer GlenHomer Glen, United StatesNo longer taking part
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, United StatesTaking people
- Swedish Cancer Institute-IssaquahIssaquah, United StatesNo longer taking part
- MU Health Care Goldschmidt Cancer CenterJefferson City, United StatesNo longer taking part
- Freeman Health SystemJoplin, United StatesNo longer taking part
- Mercy Hospital JoplinJoplin, United StatesNo longer taking part
- Jupiter Medical CenterJupiter, United StatesTaking people
- University of Kansas Cancer CenterKansas City, United StatesTaking people
- Kadlec Clinic Hematology and OncologyKennewick, United StatesNo longer taking part
- Illinois CancerCare-Kewanee ClinicKewanee, United StatesNo longer taking part
- Kingman Regional Medical CenterKingman, United StatesNo longer taking part
- UC San Diego Moores Cancer CenterLa Jolla, United StatesTaking people
- Providence Regional Cancer System-LaceyLacey, United StatesNo longer taking part
- Northwestern Medicine Lake Forest HospitalLake Forest, United StatesNo longer taking part
- Northwell Health/Center for Advanced MedicineLake Success, United StatesTaking people
- University of Michigan Health - Sparrow LansingLansing, United StatesNo longer taking part
- Alliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas, United StatesNo longer taking part
- Ann M Wierman MD LTDLas Vegas, United StatesNo longer taking part
- Comprehensive Cancer Centers of NevadaLas Vegas, United StatesNo longer taking part
- Comprehensive Cancer Centers of Nevada - Central ValleyLas Vegas, United StatesNo longer taking part
- Comprehensive Cancer Centers of Nevada - NorthwestLas Vegas, United StatesNo longer taking part
- Comprehensive Cancer Centers of Nevada - Town CenterLas Vegas, United StatesNo longer taking part
- Comprehensive Cancer Centers of Nevada-SummerlinLas Vegas, United StatesNo longer taking part
- Desert West SurgeryLas Vegas, United StatesNo longer taking part
- HealthCare Partners Medical Group Oncology/Hematology-Centennial HillsLas Vegas, United StatesNo longer taking part
- HealthCare Partners Medical Group Oncology/Hematology-Maryland ParkwayLas Vegas, United StatesNo longer taking part
- HealthCare Partners Medical Group Oncology/Hematology-San MartinLas Vegas, United StatesNo longer taking part
- HealthCare Partners Medical Group Oncology/Hematology-TenayaLas Vegas, United StatesNo longer taking part
- Hope Cancer Care of NevadaLas Vegas, United StatesNo longer taking part
- Las Vegas Cancer Center-Medical CenterLas Vegas, United StatesNo longer taking part
- Las Vegas Prostate Cancer CenterLas Vegas, United StatesNo longer taking part
- Las Vegas Urology - Cathedral RockLas Vegas, United StatesNo longer taking part
- Las Vegas Urology - PecosLas Vegas, United StatesNo longer taking part
- Las Vegas Urology - Smoke RanchLas Vegas, United StatesNo longer taking part
- Las Vegas Urology - SunsetLas Vegas, United StatesNo longer taking part
- Oncology Las Vegas - TenayaLas Vegas, United StatesNo longer taking part
- OptumCare Cancer Care at CharlestonLas Vegas, United StatesNo longer taking part
- OptumCare Cancer Care at Fort ApacheLas Vegas, United StatesNo longer taking part
- OptumCare Cancer Care at MountainViewLas Vegas, United StatesNo longer taking part
- Radiation Oncology Centers of Nevada CentralLas Vegas, United StatesNo longer taking part
- Radiation Oncology Centers of Nevada SoutheastLas Vegas, United StatesNo longer taking part
- Summerlin Hospital Medical CenterLas Vegas, United StatesNo longer taking part
- Sunrise Hospital and Medical CenterLas Vegas, United StatesNo longer taking part
- University Cancer CenterLas Vegas, United StatesNo longer taking part
- University Medical Center of Southern NevadaLas Vegas, United StatesNo longer taking part
- Urology Specialists of Nevada - CentralLas Vegas, United StatesNo longer taking part
- Urology Specialists of Nevada - NorthwestLas Vegas, United StatesNo longer taking part
- Urology Specialists of Nevada - SouthwestLas Vegas, United StatesNo longer taking part
- Beebe Medical CenterLewes, United StatesNo longer taking part
- Trinity Health Saint Mary Mercy Livonia HospitalLivonia, United StatesTaking people
- Hope Cancer ClinicLivonia, United StatesNo longer taking part
- PeaceHealth Saint John Medical CenterLongview, United StatesNo longer taking part
- Henry Ford Saint John Hospital - Macomb MedicalMacomb, United StatesTaking people
- Henry Ford Warren Hospital - Breast MacombMacomb, United StatesNo longer taking part
- Illinois CancerCare-MacombMacomb, United StatesNo longer taking part
- University of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison, United StatesNo longer taking part
- University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesNo longer taking part
- North Shore University HospitalManhasset, United StatesTaking people
- Saint Mary's Oncology/Hematology Associates of MarletteMarlette, United StatesNo longer taking part
- Marshfield Medical Center-MarshfieldMarshfield, United StatesTaking people
- Loyola University Medical CenterMaywood, United StatesTaking people
- Marjorie Weinberg Cancer Center at Loyola-GottliebMelrose Park, United StatesNo longer taking part
- Froedtert Menomonee Falls HospitalMenomonee Falls, United StatesTaking people
- Saint Luke's Cancer Institute - MeridianMeridian, United StatesNo longer taking part
- Beebe South Coastal Health CampusMillville, United StatesNo longer taking part
- Medical College of WisconsinMilwaukee, United StatesTaking people
- Marshfield Medical Center - MinocquaMinocqua, United StatesTaking people
- Saint Patrick Hospital - Community HospitalMissoula, United StatesNo longer taking part
- West Virginia University HealthcareMorgantown, United StatesNo longer taking part
- SSM Health Good SamaritanMount Vernon, United StatesNo longer taking part
- Saint Alphonsus Cancer Care Center-NampaNampa, United StatesTaking people
- Saint Luke's Cancer Institute - NampaNampa, United StatesNo longer taking part
- Froedtert and MCW Moorland Reserve Health CenterNew Berlin, United StatesTaking people
- Long Island Jewish Medical CenterNew Hyde Park, United StatesTaking people
- UC Comprehensive Cancer Center at Silver CrossNew Lenox, United StatesTaking people
- Ochsner Medical Center JeffersonNew Orleans, United StatesNo longer taking part
- NYP/Weill Cornell Medical CenterNew York, United StatesNo longer taking part
- Helen F Graham Cancer CenterNewark, United StatesTaking people
- Medical Oncology Hematology Consultants PANewark, United StatesTaking people
- Christiana Care Health System-Christiana HospitalNewark, United StatesNo longer taking part
- Delaware Clinical and Laboratory Physicians PANewark, United StatesNo longer taking part
- Providence Newberg Medical CenterNewberg, United StatesTaking people
- Cancer Care Center of O'FallonO'Fallon, United StatesNo longer taking part
- Drexel Town Square Health CenterOak Creek, United StatesTaking people
- University of Oklahoma Health Sciences CenterOklahoma City, United StatesTaking people
- Mercy Hospital Oklahoma CityOklahoma City, United StatesNo longer taking part
- Nebraska Medicine-Village PointeOmaha, United StatesNo longer taking part
- University of Nebraska Medical CenterOmaha, United StatesNo longer taking part
- UC Irvine Health- Chao Family Comprehensive Cancer CenterOrange, United StatesTaking people
- Providence Willamette Falls Medical CenterOregon City, United StatesTaking people
- University of Chicago Medicine-Orland ParkOrland Park, United StatesTaking people
- Illinois CancerCare-Ottawa ClinicOttawa, United StatesNo longer taking part
- Hope Cancer Care of Nevada-PahrumpPahrump, United StatesNo longer taking part
- Stanford Cancer Institute Palo AltoPalo Alto, United StatesNo longer taking part
- Illinois CancerCare-PekinPekin, United StatesNo longer taking part
- OSF Saint Francis Radiation Oncology at PekinPekin, United StatesNo longer taking part
- Illinois CancerCare-PeoriaPeoria, United StatesTaking people
- Methodist Medical Center of IllinoisPeoria, United StatesNo longer taking part
- OSF Saint Francis Medical CenterPeoria, United StatesNo longer taking part
- OSF Saint Francis Radiation Oncology at Peoria Cancer CenterPeoria, United StatesNo longer taking part
- Illinois CancerCare-PeruPeru, United StatesNo longer taking part
- Valley Radiation OncologyPeru, United StatesNo longer taking part
- Thomas Jefferson University HospitalPhiladelphia, United StatesNo longer taking part
- Trinity Health Saint Joseph Mercy Oakland HospitalPontiac, United StatesTaking people
- Hope Cancer CenterPontiac, United StatesNo longer taking part
- Michigan Healthcare Professionals PontiacPontiac, United StatesNo longer taking part
- Trinity Health IHA Medical Group-Alice Gustafson CenterPontiac, United StatesNo longer taking part
- Providence Portland Medical CenterPortland, United StatesTaking people
- Providence Saint Vincent Medical CenterPortland, United StatesTaking people
- Oregon Health and Science UniversityPortland, United StatesNo longer taking part
- Illinois CancerCare-PrincetonPrinceton, United StatesNo longer taking part
- Saint Charles Health System-RedmondRedmond, United StatesNo longer taking part
- Beebe Health CampusRehoboth Beach, United StatesNo longer taking part
- Radiation Oncology AssociatesReno, United StatesNo longer taking part
- Renown Regional Medical CenterReno, United StatesNo longer taking part
- Saint Mary's Regional Medical CenterReno, United StatesNo longer taking part
- Valley Medical CenterRenton, United StatesNo longer taking part
- Marshfield Medical Center-Rice LakeRice Lake, United StatesTaking people
- VCU Massey Comprehensive Cancer CenterRichmond, United StatesTaking people
- University of RochesterRochester, United StatesTaking people
- Mayo Clinic in RochesterRochester, United StatesNo longer taking part
- Henry Ford Rochester HospitalRochester Hills, United StatesNo longer taking part
- Mercy Clinic-Rolla-Cancer and HematologyRolla, United StatesNo longer taking part
- Phelps Health Delbert Day Cancer InstituteRolla, United StatesNo longer taking part
- MyMichigan Medical Center SaginawSaginaw, United StatesTaking people
- Oncology Hematology Associates of Saginaw Valley PCSaginaw, United StatesNo longer taking part
- Heartland Regional Medical CenterSaint Joseph, United StatesNo longer taking part
- Sainte Genevieve County Memorial HospitalSainte Genevieve, United StatesNo longer taking part
- TidalHealth Nanticoke / Allen Cancer CenterSeaford, United StatesNo longer taking part
- Pacific Gynecology SpecialistsSeattle, United StatesNo longer taking part
- Swedish Medical Center-Ballard CampusSeattle, United StatesNo longer taking part
- Swedish Medical Center-Cherry HillSeattle, United StatesNo longer taking part
- Swedish Medical Center-First HillSeattle, United StatesNo longer taking part
- PeaceHealth United General Medical CenterSedro-Woolley, United StatesNo longer taking part
- Providence Regional Cancer System-SheltonShelton, United StatesNo longer taking part
- CoxHealth South HospitalSpringfield, United StatesNo longer taking part
- Mercy Hospital SpringfieldSpringfield, United StatesNo longer taking part
- Mercy Medical CenterSpringfield, United StatesNo longer taking part
- Southern Illinois University School of MedicineSpringfield, United StatesNo longer taking part
- Springfield ClinicSpringfield, United StatesNo longer taking part
- Springfield Memorial HospitalSpringfield, United StatesNo longer taking part
- Mercy Hospital Saint LouisSt Louis, United StatesTaking people
- Mercy Hospital SouthSt Louis, United StatesTaking people
- Siteman Cancer Center at Christian HospitalSt Louis, United StatesTaking people
- Siteman Cancer Center-South CountySt Louis, United StatesTaking people
- Washington University School of MedicineSt Louis, United StatesTaking people
- Mercy Infusion Center - ChippewaSt Louis, United StatesNo longer taking part
- Missouri Baptist Medical CenterSt Louis, United StatesNo longer taking part
- Bhadresh Nayak MD PC-Sterling HeightsSterling Heights, United StatesNo longer taking part
- Marshfield Medical Center-River Region at Stevens PointStevens Point, United StatesTaking people
- Stony Brook University Medical CenterStony Brook, United StatesTaking people
- Missouri Baptist Sullivan HospitalSullivan, United StatesNo longer taking part
- MyMichigan Medical Center TawasTawas City, United StatesTaking people
- Saint Luke's Cancer Institute - Twin FallsTwin Falls, United StatesNo longer taking part
- PeaceHealth Southwest Medical CenterVancouver, United StatesNo longer taking part
- Providence Saint Mary Regional Cancer CenterWalla Walla, United StatesNo longer taking part
- Henry Ford Health Warren HospitalWarren, United StatesTaking people
- Henry Ford Warren Hospital - GLCMSWarren, United StatesTaking people
- Advanced Breast Care Center PLLCWarren, United StatesNo longer taking part
- Henry Ford Madison Heights Hospital - BreastWarren, United StatesNo longer taking part
- Macomb Hematology Oncology PCWarren, United StatesNo longer taking part
- Illinois CancerCare - WashingtonWashington, United StatesNo longer taking part
- Mercy Hospital WashingtonWashington, United StatesNo longer taking part
- MedStar Georgetown University HospitalWashington D.C., United StatesTaking people
- UI Health Care Mission Cancer and Blood - Waukee ClinicWaukee, United StatesTaking people
- Froedtert West Bend Hospital/Kraemer Cancer CenterWest Bend, United StatesTaking people
- Saint Mary's Oncology/Hematology Associates of West BranchWest Branch, United StatesNo longer taking part
- University of Cincinnati Cancer Center-West ChesterWest Chester, United StatesTaking people
- Marshfield Medical Center - WestonWeston, United StatesTaking people
- University of Kansas Hospital-Westwood Cancer CenterWestwood, United StatesTaking people
- Christiana Care Health System-Wilmington HospitalWilmington, United StatesNo longer taking part
- Wake Forest University Health SciencesWinston-Salem, United StatesTaking people
- North Star Lodge Cancer Center at Yakima Valley Memorial HospitalYakima, United StatesNo longer taking part
- Providence Regional Cancer System-YelmYelm, United StatesNo longer taking part
- Huron Gastroenterology PCYpsilanti, United StatesTaking people
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Cancer Institute (NCI)
- Trial code
- NCT03739814
- Record updated
- 28 October 2026
- Original description
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug, called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving inotuzumab ozogamicin and blinatumomab with or without ponatinib may be effective in treating patients with newly diagnosed, recurrent or refractory CD22 positive B-lineage acute lymphoblastic leukemia.Read full original descriptionShow less
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug, called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving inotuzumab ozogamicin and blinatumomab with or without ponatinib may be effective in treating patients with newly diagnosed, recurrent or refractory CD22 positive B-lineage acute lymphoblastic leukemia.
Inclusion: STEP 0: Submission of bone marrow aspirate and peripheral blood for MRD analysis is mandatory prior to registration; the bone marrow sample should be from the first aspiration (i.e. first pull). Aspirate needle should be redirected if needed to get first pull bone marrow aspirate. It should be initiated as soon as possible after pre-registration. The specimens should be sent to the HEME Biobank; Lumbar Puncture (Spinal Tap) and Intrathecal Methotrexate:; Patients may receive the day 1 of course IA dose of intrathecal (IT) methotrexate during the prior-to-registration lumbar puncture (or the venous line placement) to avoid a second lumbar puncture. If the dose is administered prior to registration, then systemic chemotherapy must begin within 7 days of this IT chemotherapy; STEP 1: Morphologic diagnosis of precursor B-cell acute lymphoblastic leukemia (ALL) based on World Health Organization (WHO) criteria. Patients with Burkitt lymphoma/leukemia are not eligible; STEP 1: CD22-positive disease defined as CD22 expression by >= 20% of lymphoblasts by local hematopathology evaluation; STEP 1: Philadelphia chromosome/BCR-ABL1-negative or Philadelphia chromosome/BCR-ABL1-positive B-cell ALL by cytogenetics, fluorescence in situ hybridization (FISH), and/or polymerase chain reaction (PCR); STEP 1: No active central nervous system (CNS) leukemia (i.e. only CNS-1 disease allowed). Active CNS leukemia is defined as morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF), use of CNS-directed local treatment for active disease within 28 days prior to registration, symptomatic CNS leukemia (i.e. cranial nerve palsies or other significant neurological dysfunction) within the 28 days prior to registration, and/or known asymptomatic parenchymal CNS mass lesions; see below for additional guidance. Prophylactic intrathecal medication alone is not an exclusion; Categories of CNS Involvement for CNS Evaluation Prior to Registration:; CNS 1: CSF has < 5 WBC/uL with cytospin negative for blasts; or >= 10 red blood cell (RBC)/uL with cytospin negative for blasts; CNS 2: CSF has < 5 WBC/uL with cytospin positive for blasts; or >= 10 RBC/uL with cytospin positive for blasts; or >= 10 RBC/uL, WBC/uL >= 5 but less than Steinherz/Bleyer algorithm with cytospin positive for blasts (see below); CNS 3: CSF has >= 5 WBC/uL with cytospin positive for blasts; or >= 10 RBC/uL, >= 5 WBC/uL and positive by Steinherz/Bleyer algorithm (see below); or clinical signs of CNS leukemia (such as facial nerve palsy, brain/eye involvement or hypothalamic syndrome). Steinherz/Bleyer Method of Evaluating Initial Traumatic Lumbar Punctures:; If the patient has leukemia cells in the peripheral blood and the lumbar puncture is traumatic and contains >= 5 WBC/uL with blasts, the following algorithm should be used to define CNS disease: CSF WBC/CSF RBC > 2 x (Blood WBC/Blood RBC count); STEP 1: Patients with known or suspected testicular involvement by leukemia are allowed provided that the patient receives concomitant scrotal/testicular radiotherapy; Unilateral or bilateral testicular enlargement should be assessed by ultrasound or other imaging technique. Biopsy is recommended if clinical findings are equivocal or suggestive of hydrocele or a non-leukemic mass, but further assessments are per treating physician discretion; STEP 1: Not pregnant and not nursing; This study involves agents that have known genotoxic, mutagenic, and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required; STEP 1: Eastern Cooperative Oncology Group (ECOG) performance status: 0-2; STEP 1: No unstable cardiac disease such as myocardial infarction, angina pectoris, uncontrolled heart failure, or uncontrolled cardiac arrhythmia within 6 months of registration; STEP 1: No impaired cardiac function, defined as left ventricular ejection fraction (LVEF) < 45% or New York Heart Association (NYHA) stage III or IV congestive heart failure (CHF); STEP 1: Patients with known human immunodeficiency virus (HIV) infection are eligible if they have been on effective antiretroviral therapy with an undetectable viral load tested within 6 months of registration; STEP 1: Patients with hepatitis B virus (HBV) are eligible only if they meet all the following:; On HBV-suppressive therapy; No evidence of active virus; No evidence of HBV-related liver damage; STEP 1: Patients with hepatitis C virus (HCV) are eligible only if they meet all the following:; Successfully completed complete-eradication therapy with undetectable viral load; No evidence of HCV-related liver damage; STEP 1: No history of clinically relevant neurologic disorder such as epilepsy, seizure, aphasia, stroke, severe brain injury, structural brain abnormality, benign brain tumor, dementia, Parkinson's disease, movement disorder, cerebellar disease, or other significant CNS abnormalities; STEP 1: No prior additional malignancy (i.e. in addition to ALL) except adequately treated basal- or squamous-cell skin cancer, in situ cervical cancer, stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for >= 2 years; STEP 1: No history of clinically significant ventricular arrhythmia, unexplained non-vasovagal syncope, or chronic bradycardic states such as sinoatrial block or higher degree of atrioventricular block unless a permanent pacemaker has been implanted; STEP 1: No history of chronic liver disease, including cirrhosis; STEP 1: No history of sinusoidal occlusion syndrome/veno-occlusive disease of the liver; STEP 1: No uncontrolled infection or recent history (within 4 months prior to registration) of deep tissue infections such as fasciitis or osteomyelitis; STEP 1: Total bilirubin, serum =< 1.5 x upper limit of normal (ULN)*; Except in the event of: 1) Gilbert disease, in which case total bilirubin must be =< 2 x ULN, or 2) elevated bilirubin believed by investigator to be due to leukemic infiltration, in which case total bilirubin must be =< 2 x ULN; STEP 1: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; STEP 1: Creatinine, serum =< 1.5 ULN OR creatinine clearance >= 40 mL/min; STEP 1: QT interval by Fridericia's correction formula (QTcF) =< 470 msec; COHORT 1: Age >= 60 years; COHORT 1: Diagnosis of Philadelphia chromosome/BCR-ABL1-negative B-cell ALL; COHORT 1: No prior treatment for ALL except a single dose of intrathecal chemotherapy, corticosteroids, hydroxyurea, and/or leukapheresis to reduce peripheral blast count and prevent ALL complications. Allowed therapy may be administered for no more than 14 days and must be completed >= 24 hours prior to the initiation of protocol therapy; COHORT 1: No plan for allogeneic or autologous hematopoietic cell transplantation (HCT); COHORT 2: Age >= 18 years; COHORT 2: Diagnosis of Philadelphia chromosome/BCR-ABL1-negative B-cell ALL; COHORT 2: Relapsed or refractory disease in salvage 1 or 2; COHORT 2: No isolated extramedullary relapse; COHORT 2: Prior allogeneic HCT permitted; COHORT 2: Patients with prior allogeneic HCT must have completed transplantation >= 4 months prior to registration; COHORT 2: Patients with prior allogeneic HCT must have no evidence of graft-versus-host disease and must have completed immunosuppressive therapy >= 30 days prior to registration; COHORT 2: Prior treatment with inotuzumab ozogamicin, blinatumomab, other CD22-directed therapy, or other CD19-directed therapy is not allowed; COHORT 2: Prior treatment with rituximab must be completed >= 7 days prior to registration; COHORT 2: Prior treatment with other monoclonal antibodies must be completed >= 6 weeks prior to registration; COHORT 2: Prior treatment for ALL must be completed >= 14 days prior to registration with the following exceptions: intrathecal chemotherapy, hydroxyurea, corticosteroids, 6-mercaptopurine, methotrexate, vincristine, and/or leukapheresis to reduce circulating absolute lymphoblast count to =< 10,000/uL or prevent complications related to ALL are allowed but must be completed >= 24 hours prior to the initiation of protocol therapy; COHORT 2: Patients should have resolution of any acute non-hematologic toxicities of prior therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 grade =< 1; COHORT 2: Peripheral blood absolute lymphoblast count =< 10,000/uL (treatment allowed as above to reduce blast count to =< 10,000/uL); COHORT 3: Age ≥ 75 years OR age ≥ 18 years AND ineligible for hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HyperCVAD) regimens; COHORT 3: Diagnosis of Philadelphia chromosome/BCR-ABL1-positive B-cell ALL; COHORT 3: No prior treatment for ALL except a single dose of intrathecal chemotherapy, corticosteroids, hydroxyurea, BCR-ABL1-targeted tyrosine kinase inhibitor, and/or leukapheresis to reduce peripheral blast count and prevent ALL complications. Allowed non-protocol therapy may be administered for no more than 14 days and must be completed ≥ 24 hours prior to the initiation of protocol therapy; COHORT 3: No chronic, strong CYP3A4 inducers.